Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells

被引:230
|
作者
McNutt, Markey C.
Lagace, Thomas A.
Horton, Jay D. [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA
[2] Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA
关键词
D O I
10.1074/jbc.C700095200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the proteinase K subfamily of subtilases, promotes internalization and degradation of low density lipoprotein receptors (LDLRs) after binding the receptor on the surface of hepatocytes. PCSK9 has autocatalytic activity that releases the prodomain at the N terminus of the protein. The prodomain remains tightly associated with the catalytic domain as the complex transits the secretory pathway. It is not known whether enzymatic activity is required for the LDLR-reducing effects of PCSK9. Here we expressed the prodomain together with a catalytically inactive protease domain in cells and purified the protein from the medium. The ability of the catalytically inactive PCSK9 to bind and degrade LDLRs when added to culture medium of human hepatoma HepG2 cells at physiological concentrations was similar to that seen using wild-type protein. Similarly, a catalytic-dead version of a gain-of-function mutant, PCSK9(D374Y), showed no loss of activity compared with a catalytically active counterpart; both proteins displayed similar to 10-fold increased activity in degradation of cell surface LDLRs compared with wild-type PCSK9. We conclude that the ability of PCSK9 to degrade LDLRs is independent of catalytic activity and suggest that PCSK9 functions as a chaperone to prevent LDLR recycling and/or to target LDLRs for lysosomal degradation.
引用
收藏
页码:20799 / 20803
页数:5
相关论文
共 50 条
  • [31] Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol
    Spolitu, Stefano
    Okamoto, Haruka
    Dai, Wen
    Zadroga, John A.
    Wittchen, Erika S.
    Gromada, Jesper
    Ozcan, Lale
    CIRCULATION RESEARCH, 2019, 124 (01) : 38 - 51
  • [32] Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding
    Gu, Hong-mei
    Adijiang, Ayinuer
    Mah, Matthew
    Zhang, Da-wei
    JOURNAL OF LIPID RESEARCH, 2013, 54 (12) : 3345 - 3357
  • [33] STEROL-INDEPENDENT REGULATION OF LOW-DENSITY-LIPOPROTEIN RECEPTOR (LDLR) ACTIVITY IN HEPG2 CELLS
    ELLSWORTH, JL
    CHANDRASEKARAN, C
    COOPER, AD
    ARTERIOSCLEROSIS, 1990, 10 (05): : A767 - A767
  • [34] Inhibitory effect of Cinnamomum cortex extracts on PCSK9 expression in fructose induced HepG2
    Cha, Min Ho
    Kim, Kwang-Youn
    Kim, Song-Hee
    PLANTA MEDICA, 2023, 89 (14) : 1385 - 1385
  • [35] PCSK9/LDLR Pathway Mediates Curcumin Trinicotinate Promoting Lipid Uptake of HepG2
    Zhang Cai-Ping
    Sun Shao-Wei
    Gong Yong-Zhen
    Ou Lu
    Lin Li-Mei
    Zheng Xing
    Tuo Qin-Hui
    Lei Xiao-Yong
    Liao Duan-Fang
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2015, 42 (09) : 825 - 832
  • [36] PCSK9 REDUCES HEPATIC LIPID CONTENT AND CONFERS PROTECTION AGAINST ER STRESS AND ROS IN HEPG2 CELLS
    Byun, Jae Hyun
    Lebeau, Paul
    Al-Hashimi, Ali
    Platko, Khrystyna C.
    Trigatti, Bernardo
    Seidah, Nabil G.
    Austin, Richard C.
    FASEB JOURNAL, 2018, 32 (01):
  • [37] SMALL CHEMICAL ENTITIES TARGETING PCSK9: SYNERGISTIC EFFECT WITH SIMVASTATIN ON LDL CHOLESTEROL UPTAKE BY HEPG2 CELLS
    Lupo, M. G.
    Radi, M.
    Ferri, N.
    ATHEROSCLEROSIS, 2019, 287 : E36 - E36
  • [38] The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells
    Li, Hai
    Liu, Jingwen
    BIOCHEMICAL JOURNAL, 2012, 443 : 757 - 768
  • [39] Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
    Kosenko, Tanja
    Golder, Mia
    Leblond, Geoffrey
    Weng, Willy
    Lagace, Thomas A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (12) : 8279 - 8288
  • [40] Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
    Shapiro, Michael D.
    Minnier, Jessica
    Tavori, Hagai
    Kassahun, Helina
    Flower, Andrea
    Somaratne, Ransi
    Fazio, Sergio
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (04):